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Abstract
Background: Alcohol interventions are important to the developing public health role of community pharmacies.
The Medicines and Alcohol Consultation (MAC) is a new intervention, co-produced with community pharmacists
(CPs) and patients, which involves a CP practice development programme designed to integrate discussion of
alcohol within existing NHS medicine review services. We conducted a pilot trial of the MAC and its delivery to
investigate all study procedures to inform progression to a definitive trial.
Methods: This cluster pilot RCT was conducted in 10 community pharmacies in Yorkshire, UK, with a CP from each
who regularly conducted Medicine Use Review (MUR) and New Medicine Service (NMS) consultations. Randomisation
was conducted using a secure remote randomisation service. Intervention CPs (n = 5) were trained to deliver the MAC in
MUR/NMS consultations. Control CPs (n = 5) provided these services as usual. Consecutive MUR/NMS patients were asked
by CPs to participate, screened for eligibility (consumption of alcohol at least twice per week), and baseline data collected
for those eligible. A two-month follow-up telephone interview was conducted. Blinding of CPs was not possible, but
patients were blinded to the alcohol focus of the trial. Primary outcomes were total weekly UK units (8 g of ethanol per
unit) of alcohol consumption in the week prior to follow-up, and confidence in medications management.
Trial procedures were assessed by recruitment, attrition, and follow-up rates.
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Results: 260 patients were approached by CPs to take part in the trial, 68% (n = 178) were assessed for
eligibility and 30% (n = 54) of these patients were eligible. Almost all eligible patients (n = 51; 94%) consented
to participate, of whom 92% (n = 47) were followed-up at 2 months; alcohol consumption was lower in the
intervention arm and confidence in medication management reduced slightly for both groups. Exploration of
recall issues at follow-up showed a high level of agreement between a two-item quantity/frequency measure
and 7-day guided recall of alcohol consumption.
Conclusions: The pilot trial demonstrates the feasibility of implementing the MAC in community pharmacy
and trial recruitment and data collection procedures. However, decommissioning of MURs means that it is not
possible to conduct a definitive trial of the intervention in this service.
Trial registration: ISRCTN57447996
Keywords: Alcohol, Community pharmacy, Medicine reviews, Pilot trial, Feasibility
Background
Pharmacists and pharmacy staff are the third largest pro-
fessional health workforce after nurses and doctors [1,
2]. Pharmacies in community settings in the UK now
offer a range of services to the general public designed
to promote and protect health, including medicine re-
views, sexual health screening, smoking cessation and al-
cohol interventions [3]. The UK Department of Health
and other national bodies have recommended that
pharmacy-based alcohol interventions should be piloted
and evaluated as part of the developing public health
function of community pharmacies [4–7].
We have completed the only previous randomised
controlled trial (RCT) (n = 407, follow-up 80%) of an
alcohol intervention within the community pharmacy
setting worldwide [8], apart from one small pilot trial
(n = 69, 29% follow-up) that was published in the grey
literature only [9]. Our previous trial found: community
pharmacists to be very willing to participate in an effect-
iveness trial; the community pharmacy setting to be highly
conductive to brief alcohol discussions for clinical and
public health purposes when people were approached op-
portunistically, most of whom did not see their drinking
as problematic or in need of intervention, even though
they were drinking at hazardous or harmful levels [10];
low levels of alcohol-specific knowledge and variability in
brief intervention skills among pharmacists. The RCT
found no differences in outcomes amongst those who re-
ceived a dedicated brief intervention delivered by pharma-
cists designed to help participants think about and reduce
their drinking compared to those who did not [8]. This
approach followed the format of brief interventions devel-
oped in primary care [11, 12], and we concluded that an
entirely different approach to intervention design [13],
more firmly rooted in community pharmacy practice
itself, was needed.
Firstly, rather than asking pharmacists to take on an
entirely new public health role, there is unexplored po-
tential in optimising the contribution made to health
and well-being within the core pharmaceutical role itself.
This could be achieved by integrating attention to alco-
hol within existing pharmacy service delivery, as op-
posed to having dedicated and separate consultations for
alcohol, such as we evaluated in the earlier trial [8]. This
does not negate the need for training in consultation
skills, as shown in the previous trial.
Second, understanding the reasons why people attend
community pharmacies in the first instance may provide
a basis for better targeting of interventions [12, 13].
Some pharmacy services may lend themselves better
than others to a patient assessing the impact of alcohol
on their health as the basis of considering behaviour
change. It is likely that consultations routinely made to
discuss medicine use may provide valuable opportunities
to consider the possible consequences of alcohol for the
effectiveness of medications, and on health more
generally.
This pilot trial was part of a 5-year programme that
aims to co-produce with the pharmacy profession and
with patients, and evaluate in a definitive cluster RCT,
an intervention discussing alcohol within routine medi-
cation consultations [14–19]. The new intervention, the
Medicines and Alcohol Consultation (MAC), co-produced
with pharmacists and patients [15], was designed to be in-
corporated into existing National Health Service (NHS)
services delivered by community pharmacists. Medicines
Use Reviews (MURs) and the New Medicine Service
(NMS) aim to improve patients’ understanding and use of
their medications, with the latter focused on newly pre-
scribed medication and both targeting medications for
specific long-term conditions. The aims and content of
these services are described in detail elsewhere [18].
The aim of this external pilot trial was to investigate
all study procedures to inform progression to the defini-
tive trial. Specific objectives addressed in this paper were
to investigate the following trial procedures: the feasibil-
ity of the recruitment strategy for CP and patient partici-
pants; attrition from the trial during recruitment and at
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2 month follow-up; delivery of the MAC practice devel-
opment programme for intervention CPs; measurement
of the proposed trial primary outcomes, including data
quality issues associated with alcohol consumption recall
bias.
Method
Trial design
This was a multi-site, cluster randomised controlled
pilot trial with a 1:1 allocation ratio, with a nested
participant-centred process evaluation. The trial ran
from April to October 2019. Pharmacists in community
pharmacies allocated to the intervention delivered the
MAC consultation with patients in MUR and NMS re-
views, after completing a practice development programme
(see below). Those from pharmacies randomised to the
control condition continued to provide the MUR and NMS
as usual, and recruit participants to the pilot trial in the
same manner as the intervention condition. In both cases
the MUR was the primary service promoted for recruit-
ment, and the CPs were invited to explore whether it was
also possible to recruit and deliver the MAC intervention
via the NMS.
The pilot trial received NHS research ethics approval
(REC reference19/SW/0082) and is registered with the
ISRCTN registry (ISRCTN57447996). Findings are re-
ported according to the Consolidated Standards of
Reporting Trials (CONSORT) guidelines for pilot and
feasibility studies [20].
Participants
Community pharmacists
Community pharmacies (n = 10) within one defined geo-
graphic area (within 1.5 h of travel time from York, UK)
were recruited prior to randomisation. One CP from
each pharmacy was eligible for the trial, excluding lo-
cums, trainees, and other temporary practitioners.
Briefly, after initial advertising for expressions of interest
in the trial, CPs were deemed eligible if they: conducted
MURs; were interested in the opportunity for practice
development; could attend intervention and research
training days; and confirmed that there was no planned
disruption in the pharmacy. Eligible CPs were then se-
lected on the basis of: agreeing to approach approxi-
mately 30 patients to recruit a target of 10; having
managerial approval to participate; being able to attend
training on specific days; willingness to be randomized;
and for consultations to be audio recorded (with patient
consent).
Patients
Consecutive patients recruited to the MUR/NMS as
usual were asked by CPs (in the pharmacy private con-
sultation room) if they would be interested in taking part
in a study about how pharmacists discuss patients’
health and wellbeing in medicines reviews. If patients ac-
cepted, the CP then asked if the patient would be willing
to complete a brief screening form. The form included a
single item alcohol screening question embedded in a
range of other health and service utilisation questions:
“how often do you have a drink containing alcohol?”. Pa-
tients were thus unaware of the alcohol study focus (see
blinding below). Five response categories range from
‘never’ to ‘four or more times per week’. Patients were
eligible if they consumed alcohol at least twice per week
(in addition to being aged 18 and over and eligible for
an MUR or NMS consultation). Patients were not eli-
gible if they had received treatment for alcohol in the
past 12 months. Eligible patients were provided with a
study information statement and completed an informed
consent form.
Intervention
The purpose of the MAC is to integrate attention to al-
cohol within existing pharmacist-led medicine review
services. It is designed to enhance CPs’ person-centred
consultation skills, such that alcohol consumption can
be raised with patients during medicine review consulta-
tions in connection with medications and the conditions
for which these are being taken. Underpinning the deliv-
ery of the MAC is a 6-week practice development
programme to equip CPs to support patients to discuss
and make informed decisions about their alcohol and
medication use. Thus, the intervention comprised both
the MAC practice development programme and the de-
livery of the MAC by participating CPs. The MAC
programme comprised the following components:
1 Two practice development training days. The first
day focused on core person-centred consultation
skills (e.g. asking open questions), using the MAC
in consultations, and preparing a practice development
plan. The second was scheduled 3 weeks later and
focused on the key issues identified in using the MAC
in practice and included more advanced person-
centred skills and case studies.
2 A four-page paper-based MAC guide summarising
the structure of the MAC and core content within
consultations. The MAC guide provided six steps
within which the CP could flexibly organise the
medicine review consultation to be responsive to
patient agendas and explore possible connections
between alcohol consumption, use of medicines and
the patients’ health. It was introduced to CPs in the
first training day.
3 A range of learning support resources, including
case studies, information about interplay between
alcohol and specific medications, and practice
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development exercises were offered at each
training day, with audio-recording of consultations
introduced on the second training day (see below).
4 Individually tailored weekly practice development
support site visits or telephone calls by the MAC
support team, delivered for the 3 weeks between
training days 1 and 2, and for a further 3 weeks
after training day 2 (before patient recruitment).
Audio recording of consultations (with patient
consent) were used to facilitate discussions of
practice development and use of person-centred
consultation skills and the MAC.
5 Invitation to engage in peer support (buddying in
pairs and group discussions over WhatsApp).
Follow-up procedures
Contact details and preferences for consenting partici-
pants were collected by the trial CPs. A trained re-
searcher collected outcome data by telephone from
participants 2 months after recruitment to the study.
Participants were contacted by telephone at least three
times to arrange the follow-up interview, and if unsuc-
cessful a self-completion questionnaire was posted with
a stamped addressed envelope for return.
Outcomes
Trial procedural outcomes were: recruitment of CPs; de-
livery of the MAC practice development programme; the
proportion of patients approached for the trial who ac-
cepted the initial invitation; the proportion of patients
accepting the invitation who were eligible for the trial;
the proportion of eligible patients who consented; and
the proportion of recruited participants who provided
follow-up data (interview or postal questionnaire). Can-
didate primary outcome measures for the main trial
were total weekly UK units (8 g of ethanol per unit) of
alcohol consumption in the 7 days prior to follow-up;
and confidence in medications management measured
using the PROMIS Self-Efficacy for Managing Medica-
tions and Treatment scale (6 item version) [21]. Candi-
date secondary clinical outcomes were: quality of life
measured by the EQ. 5D-5L [22]; adherence measured
by ProMAS [23]; anxiety (GAD-7) [24] and depression
(PHQ-8) [25].
Sample size
At least four clusters per arm are recommended for
cluster pilot randomised, controlled trials [26]. Assuming
an average of 8 participants per pharmacy are recruited,
we planned to recruit 80 participants from 10 pharma-
cies (equivalent to 70 participants in an individually ran-
domised trial, assuming intraclass correlation coefficient
(ICC) = 0.02). Based on earlier (unpublished) feasibility
work, we estimated that approximately a third of MUR
patients would be eligible for the trial, and each CP was
asked to approach at least 30 patients in the planned 8
weeks of patient recruitment. A trial of this size allows a
completion rate of 80% to be estimated within a 95%
confidence interval of ±9% and participation rate of 50%
within ±8% [27].
Randomisation and blinding
Randomisation of pharmacies was undertaken by an inde-
pendent statistician using minimisation (taking account of
urban vs rural setting, independents vs multiples, and
above and below median Index of Multiple Deprivation
score). Minimisation was undertaken in minimPy using
naïve minimisation with base probability 1.0 (i.e. deter-
ministic minimisation) using marginal balance as the dis-
tance measure and with minimisation factors having a
weighting of 1. Randomisation was at the level of the CP.
CPs randomised to the control continued to provide the
MUR and NMS as usual. Those randomised to the inter-
vention were exposed to the MAC programme and used
the MAC guide in consultations. By the nature of the
intervention, blinding of the CPs was not possible. Partici-
pants were blinded to the alcohol focus of the trial in
order to safeguard the unbiased evaluation of highlighting
alcohol in the MUR/NMS consultations as alcohol assess-
ment reactivity is a well-established phenomenon in trials
[28]. The study was described to potential participants by
CPs as a study to help improve medicines reviews.
Analysis
All analyses were conducted in R [29] following the
principles of intention-to-treat with participant out-
comes analysed according to their original, randomised
group, where data are available, irrespective of deviations
based on non-compliance. As this was a pilot trial, out-
comes were intended to inform planning and delivery of
a definitive trial only and thus the trial was not powered
to detect any intervention effect. Given these objectives,
we did not include those lost to follow-up in the ana-
lyses of outcomes. For the primary clinical outcomes,
mean differences and their 95% confidence intervals
were calculated using a mixed effects model including
pharmacy as a random effect and baseline measure and
treatment as fixed effects. No methods of imputation
were utilised to explore the robustness of findings to
missing data. Following developer’s guidance [30], the
PROMIS Self-Efficacy for Managing Medications and
Treatment scale raw scores (scaled up to 8 items) were
converted to t-scores. For all clinical outcomes, mean,
standard deviation, median and interquartile range
(IQR) are presented by treatment condition.
An exploratory sub-analysis was conducted for the
measurement of alcohol consumption at follow-up. The
trial design included an assessment of whether two
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single item alcohol frequency (number of drinking days
in the past 7 days) and quantity (units of alcohol con-
sumed on a typical drinking day, in the past 7 days) mea-
sures performed as well as guided retrospective 7 day
drinking recall. The retrospective measure asked partici-
pants to start with the previous day, and to recall if they
drank any alcohol on this day. If they responded “yes”,
questions were asked to establish the type, brand or
strength and quantity of each drink consumed. This pro-
cedure was repeated for each of the last 7 days, and the
information converted into units of alcohol (where one
unit approximates to 8 g of ethanol). Patients were ran-
domly allocated to a follow-up including both measure-
ment approaches, or the frequency/quantity measure
only. Agreement between the two measures was assessed
ICCs with 95% confidence intervals. Participants were
also randomised to a one or 2 month recall period for
primary care service utilisation questions (likely to be
the most frequent health service contact for this patient
group) to assess potential recall issues (data not
reported).
Results
Community pharmacist and patient recruitment
The flow of participant recruitment and retention is
shown in Fig. 1, with data for individual CPs shown in
Table 1. There were 27 CPs who expressed interest in
the trial and 10 were randomised (5 in each arm). All 5
intervention CPs completed the MAC programme, be-
fore patient recruitment commenced. Overall, 260 pa-
tients were approached by CPs to take part in the trial
during 12 weeks of recruitment, of whom 68% (n = 178;
range 19 to 100% per CP) agreed to be screened for eli-
gibility. A higher number of patients were approached in
the control arm than in the intervention arm (145 versus
115), but a higher proportion of intervention arm pa-
tients than control arm patients approached accepted
the invitation to take part (80% (n = 92) versus 59% (n =
86)). Thirty percent (n = 54; range 12 to 57% per CP) of
patients screened were eligible for the trial (i.e. drank al-
cohol twice per week or more). Almost all eligible pa-
tients consented to take part in the trial (96%; 2 refused
and 1 did not complete contact details for follow-up).
All but 6 eligible patients were recruited via the MUR. A
total of 51 patients consented. The median cluster size
was four in the intervention arm and five in the control
arm. Participant baseline demographic and clinical char-
acteristics are summarised in Table 2.
Attrition
No participants withdrew consent during the course of
the study. Four participants (8%) were lost to follow up
and did not complete the 2-month follow-up question-
naire (one in the intervention arm, three in the control
arm). A total of 44 (86%) (23 intervention, 21 control)
completed the primary alcohol measure at 2 months and
46 (90%) (22 intervention, 24 control) completed the
PROMIS. Thirty-eight (81%) completed the follow-up
data collection over the telephone and 9 (19%) com-
pleted a paper questionnaire and returned it via post.
Primary clinical outcomes
The mean number of weekly alcohol units at 2 months
was lower in the intervention arm (10.4, SD = 9.4) than
in the control arm (14.2, SD = 13.8), although there was
a higher variation in the responses in the control arm
(Table 3). The adjusted (for pharmacy and baseline
measure) mean difference was − 7.23 units (95% CI: −
17.87 to 2.99). PROMIS t-scores were lower in the inter-
vention arm (48.8, SD = 7.5) than in the control arm
(53.4, SD = 7.9). The adjusted mean difference was −
2.48 (95% CI: − 6.49 to 1.55).
Secondary clinical outcomes
PHQ-8 and GAD-7 scores at 2 months were generally
very low, indicating low levels of depression and anxiety
in the recruited participants (Table 3). EQ. 5D-5L scores
at 2 months were similar across treatment arms, with
both arms having average scores close to 1 indicating lit-
tle health-related impairment of quality of life. ProMAS
scores for adherence were also similar in both arms, in-
dicating medium to high medication adherence.
Alcohol consumption measures sub-analysis
Comparison of total weekly alcohol units calculated
from the quantity/frequency items and the guided retro-
spective 7 day drinking recall was conducted for a sub-
sample of patients randomly allocated to both measures
(n = 25). Of these, complete data were available for 19
patients and showed a high level of agreement: ICC =
0.91 (95% CI: 0.85 to 0.98). There was 100% agreement
for frequency of consumption, and for quantity the ICC
was 0.96 (95% CI: 0.93 to 0.99). In the majority of cases
(12/19) the differences between the two alcohol mea-
sures were zero. Five had small differences (between 0.5
and 2 units), and for two patients the difference was
exactly 14 units with higher estimates of consumption
for the short quantity/frequency items in comparison to
the guided retrospective 7 day drinking recall.
Discussion
The findings from this pilot trial demonstrate the feasi-
bility of conducting a definitive trial of this intervention
in key respects: the MAC was acceptable to CPs and to
patients and the MAC programme was implemented
successfully; data collection procedures at baseline and
follow-up were implemented as planned; a high propor-
tion of eligible patients consented and were recruited to
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Fig. 1 Pilot trial flow diagram
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Table 1 Patient recruitment and retention per pharmacy
Site Trial arm Approached Initial invitation accepted Eligible Recruited MUR NMS Followed- up
n n %a n %b n n n n
1 Intervention 22 22 100 4 18 4 4 0 4
2 Intervention 11 9 82 4 44 4 4 0 4
3 Intervention 16 7 44 2 29 2 2 0 2
4 Intervention 37 37 100 8 22 8 5 3 7
5 Intervention 29 17 59 7 41 6 5 1 6
6 Control 34 17 50 2 12 2 2 0 2
7 Control 31 26 84 6 23 6 6 0 4
8 Control 31 6 19 3 50 1 1 0 1
9 Control 23 14 61 5 36 5 5 0 5
10 Control 26 23 88 13 57 13 11 2 12
Total 260 178 68 54 30 51 45 6 47
Note: aProportion of patients approached who accepted the initial invitation; bProportion of patients accepting the invitation who were eligible for the trial
Table 2 Baseline demographic and health related measures
MAC (N = 24) Usual Care (N = 27) Total (N = 51)
Sex
Female 9 (38%) 14 (52%) 23 (45%)
Male 15 (62%) 13 (48%) 28 (55%)
Age (years)
Mean (SD) 70.71 (8.51) 62.78 (10.90) 66.51 (10.54)
Median (Q1, Q3) 72.50 (64.00, 75.00) 61.00 (53.00, 73.50) 67.00 (60.00, 74.00)
Min - Max 53.00–92.00 47.00–83.00 47.00–92.00
Frequency of alcohol consumption
2 to 3 times per week 17 (71%) 17 (63%) 34 (67%)
4 or more times per week 7 (29%) 10 (37%) 17 (33%)
Number of prescribed medications
Mean (SD) 4.54 (2.00) 4.58 (1.96) 4.56 (1.96)
Median (Q1, Q3) 4.00 (3.75, 6.00) 4.00 (3.25, 6.00) 4.00 (3.25, 6.00)
Min - Max 1.00–9.00 2.00–9.00 1.00–9.00
EQ 5D-5L score
Mean (SD) 0.85 (0.17) 0.75 (0.24) 0.80 (0.22)
Median (Q1, Q3) 0.89 (0.72, 1.00) 0.84 (0.69, 0.86) 0.84 (0.70, 1.00)
Min - Max 0.46–1.00 −0.10 - 1.00 −0.10 - 1.00
PROMIS raw score
Mean (SD) 26.75 (3.79) 28.41 (2.06) 27.63 (3.09)
Median (Q1, Q3) 28.00 (25.75, 30.00) 29.00 (27.50, 30.00) 29.00 (26.00, 30.00)
Min - Max 15.00–30.00 24.00–30.00 15.00–30.00
PROMIS t-score
Mean (SD) 50.51 (8.34) 54.60 (6.87) 52.67 (7.80)
Median (Q1, Q3) 49.91 (45.92, 60.74) 54.95 (49.05, 60.74) 54.95 (46.56, 60.74)
Min - Max 32.76–60.74 42.89–60.74 32.76–60.74
Stewart et al. BMC Health Services Research          (2020) 20:943 Page 7 of 10
the trial; and attrition was very low. These findings com-
pare favourably to the previous community pharmacy
trial (98% of eligible patients consented; 80% follow-up
rate at 3 months) [8], and the only previous UK medi-
cine review RCT (85% follow-up rate at 10 weeks) [31].
The latter trial was not able to record the number of pa-
tients approached who declined to take part. It is, there-
fore, not possible to calculate a comparable proportion
of eligible patients providing consent.
We made considerable efforts to support CPs conduct
the trial, but there were marked variations between sites
in the flow and recruitment of eligible patients. The ma-
jority of issues affecting patient recruitment (e.g. number
of patients eligible for an MUR or NMS, number of pa-
tients agreeing to take part in an MUR or NMS) were
outside of the control of the research team. The number
of MUR or NMS patients approached to take part in the
study was lower than anticipated and we did not meet
the recruitment target, even after extending the recruit-
ment period. By design, the target for the pilot was more
demanding than for the planned definitive trial (5 vs 3
patients per CP per month). The timing of the study
must be considered within the context of an exceptional
period of uncertainty in community pharmacy, especially
in terms of delivery of enhanced NHS services such as
the MUR and NMS. Just before the start of the study,
national changes to the NHS community pharmacy
contractual framework introduced an intermediary re-
imbursable ceiling of 200 MURs for the months April–
September, and in July, the annual limit was reduced to
250 for the financial year (it was 400 per year previ-
ously), to be followed by phasing out of the service in
2020/21 [32]. The vast majority of the pilot recruitment
took place in MURs and this was the NHS service at
the centre of our thinking for delivery of the MAC
intervention. The changes impacted on pharmacy busi-
ness plans, beyond the control of the participating
pharmacists. For example, three participating pharma-
cies reached the revised MUR limit during the study.
Discussions with the trial CPs indicated a re-orientation of
priorities in their pharmacies, with MURs given less prior-
ity than other activities, and the much lower uptake of
NMS was unable to make up the shortfall because it was
seen as more challenging and/or less appropriate. The
new community pharmacy contract means that proceed-
ing with MURs is not feasible for a definitive trial and no
longer of relevance to the NHS. We similarly concluded,
after consulting with our practitioner and patient advisory
groups, that the lack of fit with NMS consultations meant
that it is also not feasible to conduct a trial of the MAC
solely within the context of this service.
We took the opportunity to investigate data quality is-
sues associated with alcohol consumption recall bias.
The retrospective 7 day drinking measurement of con-
sumption, using aided-recall techniques and allowing
participants to describe the content and quantity of
drinks consumed for each day, produces more valid con-
sumption estimates than other approaches [33]. How-
ever, we were conscious of possible participant burden,
especially in a telephone interview. The validity of brief
two-item quantity/frequency measures for screening
purposes is established [34], but we investigated the po-
tential use of this approach for trial outcome measure-
ment purposes. Although conducted with a small sub-
sample, the findings showed a high level of agreement
between the two item and 7 day drinking recall and it
may be feasible to use the quantity/frequency measure
as a primary outcome in a definitive trial if the large
over-estimation by two participants is successfully ad-
dressed. Seven day recall of consumption provides
higher estimates than longer recall periods [35], and the
accuracy of recall deteriorates day by day [36], making
alcohol consumption intrinsically difficult to measure
without error. For example, the index week will not be
representative of usual drinking behaviour for many.
Of the two candidate primary outcomes for the main
trial, the findings for alcohol consumption were more in-
dicative of change. However, the analyses were con-
ducted to assess the appropriateness of the measures for
a definitive trial only and should be treated with caution;
Table 3 Outcomes at 2 months by treatment condition
Outcome measure MAC Usual Care
n Median (IQR) Mean (SD) n Median (IQR) Mean (SD) Adjusted mean difference
(95% CI)
Alcohol (Weekly units) 23 8(4,16) 10.4 (9.4) 21 8 (3,24) 14.2 (13.8) −7.23(−17.87, 2.99)
PROMIS t-score 22 46.6 (42.89,54.95) 48.8 (7.5) 24 53.5 (47.38,60.74) 53.4 (7.9) −2.48 (−6.49, 1.55)
PROMIS raw score 22 26 (24,29) 26.2 (2.8) 24 28.9 (26.5,30) 27.8 (3.1)
ProMAS score 22 13 (11,15) 13 (3) 23 13 (11,14) 12.3 (2.4)
PHQ-8 score 23 1 (0,3) 2.2 (2.5) 24 1.5 (0,4) 2.2 (2.4)
GAD-7 score 23 0 (0,3) 1.9 (2.9) 24 0 (0,1.5) 0.9 (1.7)
EQ 5D-5L score 23 0.8 (0.8,1) 0.9 (0.1) 24 1 (0.72,1) 0.8 (0.2)
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the confidence intervals were wide due to the issues to
do with the accuracy of the alcohol consumption meas-
ure and the small sample size.
Conclusions
This pilot trial fulfilled the set aims and objectives and
established within the context we were operating in the
feasibility of undertaking a large trial in community
pharmacies. The changes to the NHS mean that we will
not proceed to conduct a definitive trial of the MAC in
community pharmacy medicine review services, so the
value of this study is in adding to the meagre evidence-
base attesting to the feasibility of trials of medicine
review services such as NMS [31]. In parallel to the
decommissioning of MURs in community pharmacy, a
new medicine review service is to be introduced in Gen-
eral Practice (GP), the Structured Medicine Review
(SMR), alongside funding for a new GP pharmacist
workforce to lead its delivery [37]. We are now in the
position of adapting our original research plans, with the
approval of our funder, to this new service setting. This
pilot trial has provided evidence generating qualified
confidence that a trial of the MAC delivered by pharma-
cists may be feasible within GP practices, returning to
the setting in which brief interventions have been most
extensively studied [13, 38], albeit with both a different
practitioner group and approach to intervention devel-
opment [39]. The MAC aligns well with the medicines
optimisation focus of the new SMR [37] and the pro-
posed enhanced role for pharmacists in prescribing and
supporting patients with complex needs to better man-
age their medications. The pilot trial findings provide a
solid foundation for adapting the intervention and the
research to the primary care setting, with some further
feasibility work needed before a definitive trial becomes
possible.
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